Weihua Zhao

发表

Sorafenib plus triplet therapy with venetoclax, azacitidine and homoharringtonine for refractory/relapsed acute myeloid leukemia with FLT3‐ITD: A multicenter phase 2 study

Yu Wang, Xuejie Jiang, F. Huang, 2023, Journal of Internal Medicine.

Homoharringtonine Overcomes the Negative Impact of Genetic Patterns on Venetoclax Plus Azacitidine Regimen in Relapsed/Refractory Acute Myeloid Leukemia: A Multi-Center, Cohort Study

Xuejie Jiang, L. Xuan, Hua Jin, 2023, Blood.